Pamela Thomas-Graham, Chairman of CNBC, Appointed to Board of Directors of Idenix Pharmaceuticals
18 May 2005 - 11:30PM
PR Newswire (US)
Pamela Thomas-Graham, Chairman of CNBC, Appointed to Board of
Directors of Idenix Pharmaceuticals CAMBRIDGE, Mass., May 18
/PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc.
(NASDAQ:IDIX), a biopharmaceutical company engaged in the
discovery, development and commercialization of drugs for the
treatment of human viral and other infectious diseases, today
announced Pamela Thomas-Graham, Chairman of CNBC, has been elected
to the company's Board of Directors. Ms. Thomas- Graham will
replace a seat vacated by Ansbert Gadicke, who has resigned his
board position. Both of these changes are effective immediately.
"As Idenix is moving from a research and clinical organization to
that of a company with commercial products, we believe Pamela's
leadership experience and strategic insights will contribute
substantially to the Idenix Board and its committees," said
Jean-Pierre Sommadossi, chairman and chief executive officer of
Idenix. "We are pleased to have Pamela join us." Sommadossi
continued, "I want to take this opportunity to thank Ansbert for
his contributions to Idenix. His support since the founding of
Idenix in 1998 has been critical to our success to date." Ms.
Thomas-Graham is currently the Chairman of CNBC, the global
business leader in television business news. Prior to being
promoted to Chairman in February 2005, Ms. Thomas-Graham served as
President and Chief Executive Officer of CNBC, from 2001 to 2005
and as an Executive Vice President of NBC, and President and Chief
Executive Officer of CNBC.com from 1999 to 2001. Ms. Thomas-Graham
joined NBC in 1999 after 10 years at McKinsey & Company, where
she was elected partner in 1995. In addition to her work at CNBC,
Ms. Thomas- Graham is also the author of the Ivy League mystery
series published by Simon & Schuster, which includes the
bestselling novels entitled Blue Blood, A Darker Shade of Crimson
and Orange Crushed. Ms. Thomas-Graham holds a J.D. from Harvard Law
School, where she served as an editor of the Harvard Law Review,
and an M.B.A. from the Harvard Business School. Ms. Thomas-Graham
is a Phi Beta Kappa graduate of Harvard College. About Idenix
Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX) is a biopharmaceutical
company engaged in the discovery, development and commercialization
of drugs for the treatment of human viral and other infectious
diseases. Idenix's current focus is on the treatment of infections
caused by hepatitis B virus, hepatitis C virus and human
immunodeficiency virus (HIV). Idenix's headquarters are located in
Cambridge, Massachusetts. The company also has drug discovery and
development operations in Montpellier, France and drug discovery
operations in Cagliari, Italy. For further information about
Idenix, please refer to http://www.idenix.com/. Forward-looking
Statements This press release contains "forward-looking statements"
within the meaning of The Private Securities Litigation Reform Act
of 1995. Statements in this press release other than those that are
historical in nature are "forward-looking statements." Forward
looking statements, which include statements with respect to the
potential therapeutic benefits and successful development of the
company's product candidates and the company's drug discovery and
research, regulatory approval processes and commercialization
activities, are subject to numerous factors, risks and
uncertainties that may cause actual events or results to differ
materially from the company's current expectations. These risks and
uncertainties relate to the results of clinical trials and other
studies with respect to the product candidates that the company has
under development; the timing and success of submission, acceptance
and approval of regulatory filings; the company's dependence on its
collaboration with Novartis Pharma AG; the company's ability to
obtain additional funding required to conduct its research,
development and commercialization activities; the ability of the
company to attract and retain qualified personnel and the company's
ability to obtain, maintain and enforce patent and other
intellectual property protection for its product candidates and its
discoveries. These and other risks are described in greater detail
under the caption "Factors That May Affect Future Results" in the
company's quarterly report on Form 10-Q for the quarter ended March
31, 2005 and filed with the Securities and Exchange Commission and
other filings that the company makes with the Securities and
Exchange Commission. All forward-looking statements reflect the
company's expectations only as of the date of this release and
should not be relied upon as reflecting the company's views,
expectations or beliefs at any date subsequent to the date of this
release. Idenix anticipates that subsequent events and developments
may cause these views, expectations and beliefs to change. However,
while Idenix may elect to update these forward-looking statements
at some point in the future, it specifically disclaims any
obligation to do so. Contact: Idenix Pharmaceuticals, Inc. Media:
Teri Dahlman (617) 995-9905 Investors: Amy Sullivan (617) 995-9838
DATASOURCE: Idenix Pharmaceuticals, Inc. CONTACT: Media: Teri
Dahlman, +1-617-995-9905, or Investors: Amy Sullivan,
+1-617-995-9838, both of Idenix Pharmaceuticals, Inc. Web site:
http://www.idenix.com/
Copyright
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jul 2023 to Jul 2024